6tg1 - Revision history

OCA at 13:01, 24 January 2024

OCA — Wed, 24 Jan 2024 13:01:39 GMT

←Older revision		Revision as of 13:01, 24 January 2024
Line 3:		Line 3:
	<StructureSection load='6tg1' size='340' side='right'caption='[[6tg1]], [[Resolution\|resolution]] 1.60Å' scene=''>		<StructureSection load='6tg1' size='340' side='right'caption='[[6tg1]], [[Resolution\|resolution]] 1.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6tg1]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TG1 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=6TG1 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6tg1]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TG1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TG1 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=N82:~{N}-[5-[4-[[4-[[1,3-bis(oxidanylidene)isoindol-2-yl]methyl]phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]-2-[2-(dimethylamino)ethoxy]phenyl]propanamide'>N82</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene~~></td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.6Å</td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">EGFR, ERBB, ERBB1, HER1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=N82:~{N}-[5-[4-[[4-[[1,3-bis(oxidanylidene)isoindol-2-yl]methyl]phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]-2-[2-(dimethylamino)ethoxy]phenyl]propanamide'>N82</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tg1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tg1 OCA], [https://pdbe.org/6tg1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tg1 RCSB], [https://www.ebi.ac.uk/pdbsum/6tg1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tg1 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=6tg1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tg1 OCA], [~~http~~://pdbe.org/6tg1 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6tg1 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6tg1 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6tg1 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN]] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[~~http~~://omim.org/entry/211980 211980]]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.	+	[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN]] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref>	+	[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 6tg1" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6tg1" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Epidermal growth factor receptor 3D structures\|Epidermal growth factor receptor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	~~[[Category: Receptor protein-tyrosine kinase]]~~	+	[[Category: Mueller MP]]
-	[[Category: Mueller~~, M P~~]]	+	[[Category: Niggenaber J]]
-	[[Category: Niggenaber, J]]	+	[[Category: Rauh D]]
-	[[Category: Rauh, D]]	+
-	~~[[Category: Covalent inhibitor]]~~	+
-	~~[[Category: Egfr]]~~	+
-	~~[[Category: Her2]]~~	+
-	~~[[Category: Transferase~~]]	+

OCA at 07:34, 4 November 2020

OCA — Wed, 04 Nov 2020 07:34:06 GMT

←Older revision		Revision as of 07:34, 4 November 2020
Line 1:		Line 1:

	==Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b==		==Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b==
-	<StructureSection load='6tg1' size='340' side='right'caption='[[6tg1]]' scene=''>	+	<StructureSection load='6tg1' size='340' side='right'caption='[[6tg1]], [[Resolution\|resolution]] 1.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TG1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TG1 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6tg1]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TG1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TG1 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tg1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tg1 OCA], [http://pdbe.org/6tg1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tg1 RCSB], [http://www.ebi.ac.uk/pdbsum/6tg1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tg1 ProSAT]</span></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=N82:~{N}-[5-[4-[[4-[[1,3-bis(oxidanylidene)isoindol-2-yl]methyl]phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]-2-[2-(dimethylamino)ethoxy]phenyl]propanamide'>N82</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">EGFR, ERBB, ERBB1, HER1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tg1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tg1 OCA], [http://pdbe.org/6tg1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tg1 RCSB], [http://www.ebi.ac.uk/pdbsum/6tg1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tg1 ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN]] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[http://omim.org/entry/211980 211980]]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN]] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Mutated or amplified Her2 serves as a driver of non-small cell lung cancer (NSCLC) or mediates resistance toward the inhibition of its family member EGFR (epidermal growth factor receptor) with small-molecule inhibitors. Current data from clinical candidates revealed that inhibitors targeting Her2 suffer from poor response rates of less than 40%, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion (ADME) parameters, as well as MS experiments and western blot analysis substantiated our approach.
		+
		+	Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach.,Lategahn J, Hardick J, Grabe T, Niggenaber J, Jeyakumar K, Keul M, Tumbrink HL, Becker C, Hodson L, Kirschner T, Klovekorn P, Ketzer J, Baumann M, Terheyden S, Unger A, Weisner J, Muller MP, van Otterlo WAL, Bauer S, Rauh D J Med Chem. 2020 Sep 15. doi: 10.1021/acs.jmedchem.0c00870. PMID:32931277<ref>PMID:32931277</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6tg1" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Mueller MP]]	+	[[Category: Receptor protein-tyrosine kinase]]
-	[[Category: Niggenaber J]]	+	[[Category: Mueller, M P]]
-	[[Category: Rauh D]]	+	[[Category: Niggenaber, J]]
		+	[[Category: Rauh, D]]
		+	[[Category: Covalent inhibitor]]
		+	[[Category: Egfr]]
		+	[[Category: Her2]]
		+	[[Category: Transferase]]

OCA at 07:08, 30 September 2020

OCA — Wed, 30 Sep 2020 07:08:07 GMT

←Older revision		Revision as of 07:08, 30 September 2020
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6tg1 ~~is ON HOLD until Paper Publication~~	+	==Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b==
-		+	<StructureSection load='6tg1' size='340' side='right'caption='[[6tg1]]' scene=''>
-	~~Authors~~: ~~Niggenaber~~, J., ~~Mueller~~, M.P., ~~Rauh~~, D.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TG1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TG1 FirstGlance]. <br>
-	~~Description: Crystal Structure of EGFR T790M~~/~~V948R in Complex with Covalent Pyrrolopyrimidine 21b~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tg1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tg1 OCA], [http://pdbe.org/6tg1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tg1 RCSB], [http://www.ebi.ac.uk/pdbsum/6tg1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tg1 ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
-	[[Category: Mueller~~, M.P~~]]	+	__TOC__
-	[[Category: ~~Rauh, D~~]]	+	</StructureSection>
-	[[Category: ~~Niggenaber, J~~]]	+	[[Category: Large Structures]]
		+	[[Category: Mueller MP]]
		+	[[Category: Niggenaber J]]
		+	[[Category: Rauh D]]

OCA at 08:32, 23 September 2020

OCA — Wed, 23 Sep 2020 08:32:30 GMT

←Older revision		Revision as of 08:32, 23 September 2020
Line 5:		Line 5:
	Authors: Niggenaber, J., Mueller, M.P., Rauh, D.		Authors: Niggenaber, J., Mueller, M.P., Rauh, D.

-	Description: Crystal Structure of EGFR T790M/V948R with ~~covalent Her2-Inhibitor 24b~~	+	Description: Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Mueller, M.P]]		[[Category: Mueller, M.P]]
	[[Category: Rauh, D]]		[[Category: Rauh, D]]
	[[Category: Niggenaber, J]]		[[Category: Niggenaber, J]]

OCA at 05:13, 27 November 2019

OCA — Wed, 27 Nov 2019 05:13:37 GMT

←Older revision		Revision as of 05:13, 27 November 2019
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6tg1 is ON HOLD until ~~sometime in the future~~	+	The entry 6tg1 is ON HOLD until Paper Publication

	Authors: Niggenaber, J., Mueller, M.P., Rauh, D.		Authors: Niggenaber, J., Mueller, M.P., Rauh, D.

OCA: Protected "6tg1" [edit=sysop:move=sysop]

OCA — Wed, 20 Nov 2019 13:44:14 GMT

Protected "6tg1" [edit=sysop:move=sysop]

←Older revision

Revision as of 13:44, 20 November 2019

OCA: New page: '''Unreleased structure''' The entry 6tg1 is ON HOLD until sometime in the future Authors: Niggenaber, J., Mueller, M.P., Rauh, D. Description: Crystal Structure of EGFR T790M/V948R wi...

OCA — Wed, 20 Nov 2019 13:44:12 GMT

New page: '''Unreleased structure''' The entry 6tg1 is ON HOLD until sometime in the future Authors: Niggenaber, J., Mueller, M.P., Rauh, D. Description: Crystal Structure of EGFR T790M/V948R wi...

New page

'''Unreleased structure'''

The entry 6tg1 is ON HOLD until sometime in the future

Authors: Niggenaber, J., Mueller, M.P., Rauh, D.

Description: Crystal Structure of EGFR T790M/V948R with covalent Her2-Inhibitor 24b
[[Category: Unreleased Structures]]
[[Category: Mueller, M.P]]
[[Category: Rauh, D]]
[[Category: Niggenaber, J]]